Karyopharm Therapeutics
KPTI
KPTI
129 hedge funds and large institutions have $340M invested in Karyopharm Therapeutics in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 30 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
129
Holders Change
-25
Holders Change %
-16.23%
% of All Funds
2.06%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
18
Increased
52
Reduced
30
Closed
43
Calls
$1.03M
Puts
$515K
Net Calls
+$519K
Net Calls Change
-$184K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.97M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.35M |
| 3 |
Barclays
London,
United Kingdom
|
+$7.01M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.24M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$6M |
Top Sellers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$15M |
| 2 |
AC
Armistice Capital
New York
|
-$13.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.77M |
| 4 |
CC
Commodore Capital
New York
|
-$6.58M |
| 5 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$6.55M |
